Leidos Holdings, Inc. Q2 FY26 Earnings Analysis

- Intelligence and Digital segment revenues grew 7% YoY, driven by recent contract awards and acquisitions, indicating continued growth. - Nearly 70% of the next 12-month pipeline is focused on new business and takeaway activity, skewed towards growth opportunities. - The $10 billion order pipeline from the Entrust acquisition is expected to convert rapidly, with orders liquidated within 1-2 years, supporting near-term revenue growth. - The Health business expects elevated volumes to continue in the near term, with growth opportunities in digital health services like Military OneSource and My Service Treatment Record pilot. - Digital infrastructure and cybersecurity offerings aligned with AI integration position the company for scalable growth. - The Defense Tech business is bullish on demand, especially in maritime autonomy and space, anticipating sizable future awards. - Overall, the company anticipates step-function growth in revenue building in Q3 and Q4, continuing into 2027.

- Leidos raised its 2026 revenue guidance by $500 million to a range of $18 billion to $18.4 billion. - Non-GAAP diluted EPS guidance increased by $0.05, now expected between $12.10 and $12.50. - Operating cash flow guidance was raised by $50 million to approximately $1.8 billion. - Entrust acquisition is expected to be accretive to non-GAAP EPS and cash in 2026, with greater accretion from synergies in 2027 and beyond. - Defense business profitability expected to improve as ramp-up progresses on higher-margin programs. - Health segment margins forecasted to remain above 20%, supported by operational and technology improvements. - Q2 expected to be a low point in revenue and margin with growth momentum building in Q3 and Q4. - Long-term outlook remains bullish, with growth driven by AI integration, digital infrastructure, and expanding managed health services.

- Leidos has planned a significant increase in CapEx for 2026, targeting up to $350 million, marking a tripling from prior levels. - Q1 2026 CapEx was $31 million, lower than initially anticipated, with expectations for higher spend in Q2. - The elevated CapEx is for a fixed, finite period to support production programs, possibly extending into early 2027. - They formed a joint venture (JV) with Analogic for the SES business to avoid high capital intensity directly on Leidos. - Leidos is cautious, earmarking capital but only deploying it when necessary, emphasizing disciplined cash stewardship. - A multiyear $100 million strategic investment in a leading PE firm provides access to high-growth disruptors in AI, cyber, and autonomy. - CapEx investment is focused on growth areas and innovation to maintain competitive advantage without committing to perpetual high spending.

- No new fundraising through debt or equity is explicitly mentioned in the provided pages. - The company closed the Entrust acquisition using a mix of $500 million cash on hand, $500 million commercial paper, and $1.4 billion in new bonds. - Post-acquisition, they borrowed less than planned and have started paying down commercial paper early. - The commercial paper balance was $300 million at the end of Q1, expected to be paid off through 2026. - The company emphasizes strong cash flow generation and disciplined capital management. - They repurchased $200 million of stock as part of capital deployment strategy. - The balance sheet shows $6.3 billion debt and $457 million cash, with a leverage ratio of 2.6x, providing ample capacity for investment aligned with strategy. - No indications of immediate or planned equity issuance or additional debt fundraising disclosed.

- Entrust business has an approximately $10 billion order pipeline. - The Entrust order pipeline is characterized by shorter cycle times, with orders typically liquidated within 1 to 2 years, allowing rapid order booking and growth. - The overall Leidos book-to-bill ratio was 0.8 in the recent quarter and 1.1x for the trailing 12 months, indicating solid award activity. - The Defense segment expects multiple potential product line awards contributing to growth. - The Health segment anticipates scaling with awards like the Military OneSource and My Service Treatment Record Pilot. - Near-term procurement activity is expected to pick up significantly over the course of the year. - The second quarter may be a revenue and margin low point due to timing and investment, but strong growth momentum is expected in Q3 and Q4.